Weekly versus daily dosing of atorvastatin.
Twenty-four consecutive patients of a single family physician who had achieved NCEP-II goal levels of low-density lipoprotein cholesterol (LDL-C) on a daily atorvastatin dose of 10 mg for at least 6 months were invited to switch to 20 mg weekly. Mean LDL levels for the 22 patients who completed the trial had been reduced by 43% from baseline on 10 mg daily (P <.05) and were reduced by 22% from baseline on the seventh day following the last weekly dose of 20 mg (P <.05). Total cholesterol to high-density lipoprotein cholesterol (TC/HDL-C) ratios were reduced by 31% and 17%, respectively (both P <.05) and triglycerides by 20% and 10% (both P <.05).
Iliff
R Douglas
RD
douglasiliff@cs.com
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000069059:Atorvastatin; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000191:economics; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011758:Pyrroles / Q000008:administration & dosage* / Q000191:economics; D014481:United States
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin